KR910000163A - 고형 약학제제 및 이의 제조방법 - Google Patents

고형 약학제제 및 이의 제조방법 Download PDF

Info

Publication number
KR910000163A
KR910000163A KR1019890007676A KR890007676A KR910000163A KR 910000163 A KR910000163 A KR 910000163A KR 1019890007676 A KR1019890007676 A KR 1019890007676A KR 890007676 A KR890007676 A KR 890007676A KR 910000163 A KR910000163 A KR 910000163A
Authority
KR
South Korea
Prior art keywords
solid pharmaceutical
vitamin
compound
pharmaceutical formulation
oily substance
Prior art date
Application number
KR1019890007676A
Other languages
English (en)
Inventor
다다시 마끼노
고지 도이
마사요시 마쓰오까
도시하루 쓰보이
Original Assignee
요시다 쇼지
센주세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 요시다 쇼지, 센주세이야꾸 가부시끼가이샤 filed Critical 요시다 쇼지
Publication of KR910000163A publication Critical patent/KR910000163A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

고형 약학제제 및 이의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (17)

  1. 다소디움 아데노신 트리포스페이트와, 비타민 B1, 활성을 갖는 비타민 B1염과 비타민 B1유도체로 구성된 군에서 건택된 화합물을 함유하는 고형 약학 제제.
  2. 제1항에 있어서, 지온용융 지방 또는 유상물질을 더 함유하고 있는 고형 약학 제제.
  3. 제2항에 있어서, 저온 용융 지방 또는 유상물질이 탄화수소, 고급지방산, 고급알코올, 폴리히드릭 알코올 지방산 에스테르, 폴리히드릭 알코올 고급 알코올 에테르 및 알킬렌 옥사이드 중합체 또는 공중합체로 구성된 군에서 선택된 물질인 고형 약학제제.
  4. 제2항 또는 제3항에 있어서, 저온용융 지방 또는 유상물질의 양이 디소디움 아데노신 트리포스페이트의 매1중량부당 적어도 0.1중량부인 고형 약학제제.
  5. 제1항, 2항 또는 3항에 있어서, 인간 안정피로의 치료제로서 작용하는 고형 약학 제제.
  6. 제1항, 2항 또는 3항에 있어서, 제제가 정제, 과립제, 산제 또는 캡슐제의 형태로 있는 고형약학 제제.
  7. 제1항, 2항 또는 3항에 있어서, 인간 안정피로의 치료제로서 작용하고 선택된 화합물이 푸르실 티아민 또는 그들의 염인 고형 약학 제제.
  8. 제7항에 있어서, 선택된 화합물이 푸르설 티아민 히드로 클로라이드인 고형 약학 제제.
  9. 디소디움 아데노신 트리포스페이트와, 비타민 B1활성을 갖는 비타민 B1유도체로 구성된 군에서 선택된 화합물을 함유하는 고형 약학 제제를 안정피로로 고통받은 인간에게 경구 투여함을 특징으로 하는 인간의 안정피로 치료 방법.
  10. 제9항에 있어서, 디소디움 아데노신 트리포스페이트와 선택된 화합물의 1일 복용량이 안정 피로로 고통받는 인간의 체중㎏당 각각 대략 0.7 내지 7㎎ 및 대략 0.2 내지 5㎎인 안정 피로 치료방법.
  11. 제9항 또는 10항에 있어서, 선택된 화합물이 푸르설 티아민 또는 그들의 염인 안정피로 치료방법.
  12. 제11항에 있어서, 선택된 화합물이 푸르설 티아민 히드로클로라이드인 안정피로 치료방법.
  13. 저온용융 지방 또는 유상물질을 적어도 디소디움 아데노신 트리포스페이트와 혼합하고, 결과된 혼합물을 가압하에 성형하고, 및 그렇게 수득된 고형 제제를 비타민 B1활성을 갖는 비타민 B1염과 비타민 B1유도체로 구성된 군에서 선택된 화합물을 함유하는 조성물 코우팅시키거나 또는 혼합함을 특징으로 하는 고형 약학 제제의 제조방법.
  14. 제13항에 있어서, 저온용융 지방 또는 유상물질이 탄화수소, 고급지방산, 고급알코올, 폴리히드릭 알코올 지방산 에스테르, 폴리히드릭 알코올 고급 알코올 에테르 및 알킬렌 옥사이드 중합체 도는 공중합체로 구성되는 군에서 선택된 물질인 고형약학 제제의 제조방법.
  15. 제13항 또는 제14항에 있어서, 제제가 정제, 과립제, 산제 또는 캡슐제의 형태로 있는 고형약학 제제의 제조방법.
  16. 제13항 또는 제14항에 있어서, 상술된 화합물이 푸르설티아민 또는 그들의 염인 고형약학 제제의 제조방법.
  17. 제16항에 있어서, 상술된 화합물이 푸르설티아민 히드로클로라이드인 고형 약학 제제의 제조방법.
    ※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890007676A 1988-06-03 1989-06-03 고형 약학제제 및 이의 제조방법 KR910000163A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63137925A JPH01308232A (ja) 1988-06-03 1988-06-03 固型医薬およびその製造法
JP63-137925 1988-06-03

Publications (1)

Publication Number Publication Date
KR910000163A true KR910000163A (ko) 1991-01-29

Family

ID=15209888

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890007676A KR910000163A (ko) 1988-06-03 1989-06-03 고형 약학제제 및 이의 제조방법

Country Status (8)

Country Link
US (1) US5017564A (ko)
EP (1) EP0348688B1 (ko)
JP (1) JPH01308232A (ko)
KR (1) KR910000163A (ko)
AT (1) ATE74768T1 (ko)
DE (1) DE68901216D1 (ko)
ES (1) ES2032628T3 (ko)
GR (1) GR3004440T3 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634374B1 (fr) * 1988-07-19 1993-10-15 Laboratoires Serobiologiques Agents photoprotecteurs, cytophotoprotecteurs cutanes ayant une activite photoprotectrice des cellules constitutives, fonctionnelles de la peau, en particulier des cellules de langerhans, a base de composes nucleiques : nucleoprotides, ribonucleotides et desoxyribonucleotides, ribonucleosides et desoxyribonucleosides, compositions cosmetiques ou dermo-pharmaceutiques contenant un tel agent ainsi que des nouveaux composes en soi
US7348315B2 (en) 1995-03-23 2008-03-25 The University Of Connecticut Methods of treating heart failure with modified ATP, ADP and AMP compounds
US5712258A (en) * 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions
US6723737B1 (en) * 1999-10-20 2004-04-20 Eliezer Rapaport Methods, pharmaceutical and therapeutic compostions for administering adenosine
WO2001028528A1 (en) * 1999-10-20 2001-04-26 Eliezer Rapaport Methods, pharmaceutical and therapeutic compositions for administering adenosine
US20030069203A1 (en) * 2001-06-04 2003-04-10 Lee Steve S. Method for increasing human performance by reducing muscle fatigue and recovery time through oral administration of adenosine triphosphate
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
JP2003119139A (ja) * 2001-10-12 2003-04-23 Ss Pharmaceut Co Ltd 疲労回復医薬組成物
US6585996B1 (en) 2002-03-13 2003-07-01 Westlake Laboratories, Inc. Lipid-soluble thiamine derivatives in the treatment of autism
US20050070701A1 (en) * 2003-09-29 2005-03-31 Hochstetler Spencer Erich Detection of living cells in polymers or pigments
ITMI20041772A1 (it) * 2004-09-17 2004-12-17 Bioprogress Spa Formulazione a rilascio controllato di tiamina e loro impiego nel trattamento di patologie collegate a difetti nei processi di apprendimento e memorizzazione.
JP5032310B2 (ja) * 2005-05-27 2012-09-26 興和株式会社 疲労回復のための医薬
TW200812601A (en) * 2006-05-30 2008-03-16 Kowa Co Medicine for recovering from fatigue
CN101478981A (zh) * 2006-06-27 2009-07-08 兴和株式会社 用于预防疲劳和/或疲劳恢复的药品
EP3875092A4 (en) * 2018-11-02 2021-12-22 Kyungpook National University Industry-Academic Cooperation Foundation COMPOSITION FOR THE PREVENTION OR TREATMENT OF MACULAR DEGENERATION
SG11202111084WA (en) * 2019-05-06 2021-11-29 Ferrer Int Multilayer pharmaceutical or nutraceutical solid dosage forms comprising pyrimidine and/or purine derivatives and b vitamins, preparation and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2775521A (en) * 1953-09-29 1956-12-25 Hoffmann La Roche Method of fortifying grain products and the resulting product
US3037911A (en) * 1959-09-04 1962-06-05 Merck & Co Inc Chewable, palatable, vitamin b preparations
US3308217A (en) * 1965-02-09 1967-03-07 Lowy Lawrence Method of granulating materials for subsequent forming into tablets
SE352811B (ko) * 1971-06-04 1973-01-15 Pharmacia Ab
GB1431841A (en) * 1973-01-15 1976-04-14 Evans S C Ophthalmic-nutritional preparations
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
FR2358155A1 (fr) * 1976-07-15 1978-02-10 Lapinet Eugene Composition pour le traitement et la prevention de l'irritation et de l'inflammation de la peau, de l'oeil et des muqueuses
US4382924A (en) * 1980-06-25 1983-05-10 The Procter & Gamble Company Palatable composition containing oil or oil-like materials
FR2557452B1 (fr) * 1983-12-28 1986-08-14 Roussel Uclaf Nouvelles compositions pour les soins de la peau renfermant de l'huile d'onagre et des traits tissulaires de rate
US4713245A (en) * 1984-06-04 1987-12-15 Mitsui Toatsu Chemicals, Incorporated Granule containing physiologically-active substance, method for preparing same and use thereof
US4764388A (en) * 1985-01-25 1988-08-16 Nabisco Brands, Inc. Method for making vitamin enriched cereal
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
JPH0816066B2 (ja) * 1986-07-18 1996-02-21 エーザイ株式会社 持続性薬効製剤
US4871718A (en) * 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair

Also Published As

Publication number Publication date
GR3004440T3 (ko) 1993-03-31
EP0348688A1 (en) 1990-01-03
ES2032628T3 (es) 1993-02-16
JPH01308232A (ja) 1989-12-12
EP0348688B1 (en) 1992-04-15
US5017564A (en) 1991-05-21
ATE74768T1 (de) 1992-05-15
DE68901216D1 (de) 1992-05-21

Similar Documents

Publication Publication Date Title
KR910000163A (ko) 고형 약학제제 및 이의 제조방법
CA1163561A (en) Preparation containing nitroglycerine and optionally other medicaments and preparation thereof
EP0165352A3 (en) Clear micellized solutions of fat soluble essential nutrients
PT92069A (pt) Processo para a producao de um sistema de distribuicao de drogas
IL64091A (en) Arylimidazo(1,2-a)pyridine acetamide derivatives,their preparation and pharmaceutical compositions containing them
US4612194A (en) Anti-rheumatic agents and their use
HU892559D0 (en) Process for the preparation of transdermal pharmaceutical composition suitable for systemic administration, containing deprenyl as active ingredient
IE861813L (en) New Polysaccharide Esters and their Salts
DE68915695D1 (de) Zubereitungen mit kontrollierter Wirkstoffabgabe.
FI96095C (fi) Menetelmä jatkuvavapautteisen lääkevalmisteen valmistamiseksi
BR9401199A (pt) Preparados de medicamentos, processo para a preparação de um preparado de medicamento, processo para a preparação de uma formulação de medicamento.
BR9807319A (pt) Microgrânulos com liberação controlada, para administração oral, contendo cisplatina, processo de preparação dos mesmos, preparação farmacêutica, e, utilização dos microgrânulos.
FR2698788B1 (fr) Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
WO1987004926A3 (en) Method of modifying the lipid structure of cell membranes and pharmaceutical compositions for use therein
AU621763B2 (en) Stable tretinoin emulsified cream formulations
IE820539L (en) Substituted biphenyl compounds
ES555118A0 (es) Metodo de preparar medicamentos que incluyen un agente buscador de hueso y un inhibidor de anhidrasa carbonica, para impedir y curar enfermedades oseas.
US4034114A (en) Treatment of skin keratoses with retinal
FR2712809B1 (fr) Nouvelle composition pharmaceutique destinée à la préparation d'une poudre stable contenant, à titre d'ingrédient actif, une association d'acide acétylsalicylique et de métoclopramide.
US3426131A (en) Medicament based on a salt of pyridoxamine
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
ES8201955A1 (es) Un procedimiento de produccion de derivados del acido 2-hi- droxioxanilico
ES8702140A1 (es) Un procedimiento para la preparacion de una composicion de etoposido en forma de dosis unitaria para administracion oral
BE900780A (fr) DERIVES DE LA CHLORO-4-FURO (3,4-c)-PYRIDINE, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS THERAPEUTIQUES A BASE DE CES DERIVES.
EP0238198A3 (en) Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid